PT3366305T - Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos - Google Patents

Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos

Info

Publication number: PT3366305T
Authority: PT; Portugal
Prior art keywords: methods; variable domains; single variable; immunoglobulin single; treating ttp
Prior art date: 2014-06-16

Application number

PT181536715T

Other languages

English (en)

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-16

Filing date

2015-06-16

Publication date

2020-12-21

2015-06-16 Application filed by Ablynx Nv filed Critical Ablynx Nv

2020-12-21 Publication of PT3366305T publication Critical patent/PT3366305T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PT181536715T 2014-06-16 2015-06-16 Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos PT3366305T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL2013007A NL2013007B1 (en)	2014-06-16	2014-06-16	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P	2014-07-30	2014-07-30

Publications (1)

Publication Number	Publication Date
PT3366305T true PT3366305T (pt)	2020-12-21

Family

ID=51541255

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PT157298290T PT3154569T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536764T PT3332800T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
PT181536749T PT3335724T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536715T PT3366305T (pt)	2014-06-16	2015-06-16	Métodos de tratamento de ttp com domínios variáveis únicos de imunoglobulina e seus usos
PT181536731T PT3335723T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PT157298290T PT3154569T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt
PT181536764T PT3332800T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt
PT181536749T PT3335724T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização no tratamento da ptt

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT181536731T PT3335723T (pt)	2014-06-16	2015-06-16	Domínios variáveis únicos de imunoglobulina para utilização em métodos de tratamento da ptt

Country Status (15)

Country	Link
US (5)	US10858445B2 (pt)
EP (6)	EP3366305B1 (pt)
JP (3)	JP6688746B2 (pt)
KR (2)	KR102403388B1 (pt)
CN (1)	CN106559985A (pt)
AU (2)	AU2015276237B2 (pt)
CA (1)	CA2952103A1 (pt)
ES (5)	ES2843642T3 (pt)
IL (1)	IL249540B (pt)
NL (1)	NL2013007B1 (pt)
PL (5)	PL3366305T3 (pt)
PT (5)	PT3154569T (pt)
RU (1)	RU2704444C2 (pt)
SG (2)	SG10201811109PA (pt)
WO (1)	WO2015193326A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) *	2017-07-13	2019-07-05	徐州医科大学	一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
MX2020008294A (es)	2018-02-06	2020-11-18	Ablynx Nv	Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.
IL302984A (en) *	2020-11-18	2023-07-01	Green Cross Corp	Adamts13 variant having increased escaping rate or activity against autoantibody
WO2023044272A1 (en)	2021-09-17	2023-03-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
US20240409666A1 (en) *	2021-12-10	2024-12-12	Renhao Li	Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB335768A (en)	1929-10-24	1930-10-02	Jacoviac Maurice	Improvements in protecting devices for gramophone disc records
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en)	1987-05-01	1997-10-14	Scripps Research Inst	Protein fragments containing factor VIII binding domain of von willebrand factor
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
ATE427968T1 (de)	1992-08-21	2009-04-15	Univ Bruxelles	Immunoglobuline ohne leichtkette
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
WO2000046383A2 (en)	1999-02-05	2000-08-10	Rijksuniversiteit Leiden	Method of modulating metabolite biosynthesis in recombinant cells
WO2001009300A2 (en)	1999-08-02	2001-02-08	Keygene N.V.	Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
US20060073141A1 (en)	2001-06-28	2006-04-06	Domantis Limited	Compositions and methods for treating inflammatory disorders
AU2003251238A1 (en)	2002-08-07	2004-02-25	Umc Utrecht Holding B.V.	Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt)	2002-10-23	2021-05-25	Ludwig Inst For Cancer Res Ltd	dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
JP2006517789A (ja)	2003-01-10	2006-08-03	アブリンクスエン．ヴェー．	治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
RU2524129C2 (ru)	2003-01-10	2014-07-27	Аблинкс Н.В.	Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en)	2003-01-23	2008-12-02	Unspam, Llc.	Method and apparatus for a non-revealing do-not-contact list system
AU2003264053A1 (en)	2003-08-12	2005-03-10	William M. Yarbrough	Treatment for acne vulgaris and method of use
US7270976B2 (en) *	2004-07-19	2007-09-18	American Diagnostica, Inc.	Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en)	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20080107601A1 (en)	2004-10-13	2008-05-08	Ablynx N.V.	Nanobodies Tm Against Amyloid-Beta and Polypeptides Comprising the Same for the Treatment of Degenerative Neural Diseases Such as Alzheimer's Disease
JP4829897B2 (ja)	2005-01-14	2011-12-07	アブリンクスナームローゼフェンノートシャップ	血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
PL2444424T3 (pl) *	2005-05-20	2019-01-31	Ablynx N.V.	Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
US8629244B2 (en)	2006-08-18	2014-01-14	Ablynx N.V.	Interleukin-6 receptor binding polypeptides
AU2008219216A1 (en)	2007-02-21	2008-08-28	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
NZ581097A (en)	2007-05-24	2012-03-30	Ablynx Nv	Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2718081A1 (en)	2008-03-21	2009-09-24	Ablynx Nv	Von willebrand factor specific binders and methods of use therefor
WO2010056550A1 (en)	2008-10-29	2010-05-20	Wyeth Llc	Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko)	2008-10-29	2016-02-11	아블린쓰 엔.브이.	단일 도메인 항원 결합 분자의 제형
EP2506874A1 (en)	2009-12-01	2012-10-10	Ablynx N.V.	Von willebrand factor specific binding agents and uses thereof
LT3757126T (lt) *	2010-11-05	2025-12-10	Novartis Ag	Psoriazinio artrito gydymo būdas, panaudojant il-17 antagonistus
DK3412305T3 (da)	2011-06-10	2021-03-01	Baxalta GmbH	Behandling af koagulationssygdom ved administration af rekombinant vwf
MY167125A (en)	2011-08-17	2018-08-13	Glaxo Group Ltd	Modified proteins and peptides
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2020008294A (es)	2018-02-06	2020-11-18	Ablynx Nv	Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina.

2014
- 2014-06-16 NL NL2013007A patent/NL2013007B1/en active
2015
- 2015-06-16 CA CA2952103A patent/CA2952103A1/en not_active Abandoned
- 2015-06-16 PT PT157298290T patent/PT3154569T/pt unknown
- 2015-06-16 EP EP18153671.5A patent/EP3366305B1/en active Active
- 2015-06-16 ES ES18153671T patent/ES2843642T3/es active Active
- 2015-06-16 PT PT181536764T patent/PT3332800T/pt unknown
- 2015-06-16 CN CN201580040020.4A patent/CN106559985A/zh active Pending
- 2015-06-16 ES ES18153673T patent/ES2915473T3/es active Active
- 2015-06-16 PL PL18153671T patent/PL3366305T3/pl unknown
- 2015-06-16 EP EP18153674.9A patent/EP3335724B1/en active Active
- 2015-06-16 AU AU2015276237A patent/AU2015276237B2/en active Active
- 2015-06-16 EP EP18153676.4A patent/EP3332800B1/en active Active
- 2015-06-16 KR KR1020177001152A patent/KR102403388B1/ko active Active
- 2015-06-16 ES ES18153674T patent/ES2924199T3/es active Active
- 2015-06-16 SG SG10201811109PA patent/SG10201811109PA/en unknown
- 2015-06-16 PL PL15729829T patent/PL3154569T3/pl unknown
- 2015-06-16 PL PL18153676T patent/PL3332800T3/pl unknown
- 2015-06-16 SG SG11201610488QA patent/SG11201610488QA/en unknown
- 2015-06-16 PT PT181536749T patent/PT3335724T/pt unknown
- 2015-06-16 EP EP15729829.0A patent/EP3154569B1/en active Active
- 2015-06-16 RU RU2017100077A patent/RU2704444C2/ru active
- 2015-06-16 PL PL18153673.1T patent/PL3335723T3/pl unknown
- 2015-06-16 PL PL18153674.9T patent/PL3335724T3/pl unknown
- 2015-06-16 PT PT181536715T patent/PT3366305T/pt unknown
- 2015-06-16 JP JP2016573549A patent/JP6688746B2/ja active Active
- 2015-06-16 ES ES18153676T patent/ES2831865T3/es active Active
- 2015-06-16 US US15/319,467 patent/US10858445B2/en active Active
- 2015-06-16 PT PT181536731T patent/PT3335723T/pt unknown
- 2015-06-16 EP EP22172948.6A patent/EP4059513A1/en not_active Withdrawn
- 2015-06-16 ES ES15729829T patent/ES2881331T3/es active Active
- 2015-06-16 WO PCT/EP2015/063493 patent/WO2015193326A1/en not_active Ceased
- 2015-06-16 EP EP18153673.1A patent/EP3335723B1/en active Active
- 2015-06-16 KR KR1020227012546A patent/KR102568585B1/ko active Active
2016
- 2016-12-13 IL IL249540A patent/IL249540B/en unknown
2018
- 2018-01-26 US US15/880,978 patent/US12269893B2/en active Active
- 2018-01-26 US US15/881,055 patent/US20180155443A1/en not_active Abandoned
- 2018-01-26 US US15/880,870 patent/US20180155440A1/en not_active Abandoned
- 2018-01-26 US US15/881,003 patent/US10919980B2/en active Active
2020
- 2020-01-30 JP JP2020014229A patent/JP7105260B2/ja active Active
2021
- 2021-05-03 AU AU2021202747A patent/AU2021202747B2/en active Active
2022
- 2022-07-11 JP JP2022110921A patent/JP2022160431A/ja active Pending

Also Published As

Publication number	Publication date
JP6688746B2 (ja)	2020-04-28
US10858445B2 (en)	2020-12-08
HK1256730A1 (en)	2019-10-04
EP3335724A1 (en)	2018-06-20
HK1256731A1 (en)	2019-10-04
SG11201610488QA (en)	2017-01-27
AU2021202747A1 (en)	2021-05-27
HK1258508A1 (en)	2019-11-15
PL3335724T3 (pl)	2022-09-19
IL249540A0 (en)	2017-02-28
KR20170015513A (ko)	2017-02-08
PT3335724T (pt)	2022-08-02
US20180155442A1 (en)	2018-06-07
RU2017100077A3 (pt)	2018-12-25
EP4059513A1 (en)	2022-09-21
WO2015193326A1 (en)	2015-12-23
ES2881331T3 (es)	2021-11-29
NL2013007B1 (en)	2016-07-05
EP3332800B1 (en)	2020-08-26
EP3335723A1 (en)	2018-06-20
JP2017519762A (ja)	2017-07-20
PL3366305T3 (pl)	2021-06-14
ES2831865T3 (es)	2021-06-09
PT3332800T (pt)	2020-11-19
KR20220053040A (ko)	2022-04-28
KR102568585B1 (ko)	2023-08-18
JP2020097600A (ja)	2020-06-25
CN106559985A (zh)	2017-04-05
PL3154569T3 (pl)	2021-11-02
EP3154569B1 (en)	2021-04-21
RU2019131713A (ru)	2019-11-11
US20180155441A1 (en)	2018-06-07
EP3154569A1 (en)	2017-04-19
JP2022160431A (ja)	2022-10-19
EP3332800A1 (en)	2018-06-13
US10919980B2 (en)	2021-02-16
EP3335724B1 (en)	2022-06-22
RU2704444C2 (ru)	2019-10-28
EP3366305B1 (en)	2020-11-18
US20180155440A1 (en)	2018-06-07
PL3332800T3 (pl)	2021-04-19
EP3335723B1 (en)	2022-03-30
EP3366305A1 (en)	2018-08-29
CA2952103A1 (en)	2015-12-23
ES2915473T3 (es)	2022-06-22
US20170210822A1 (en)	2017-07-27
AU2015276237B2 (en)	2021-02-25
RU2017100077A (ru)	2018-07-12
KR102403388B1 (ko)	2022-06-03
JP7105260B2 (ja)	2022-07-22
IL249540B (en)	2021-09-30
PT3154569T (pt)	2021-06-22
AU2021202747B2 (en)	2024-02-15
ES2924199T3 (es)	2022-10-05
US20180155443A1 (en)	2018-06-07
SG10201811109PA (en)	2019-01-30
PL3335723T3 (pl)	2022-07-18
US12269893B2 (en)	2025-04-08
PT3335723T (pt)	2022-05-20
AU2015276237A1 (en)	2017-01-19
ES2843642T3 (es)	2021-07-19

Publication	Publication Date	Title
IL304117A (en)	2023-09-01	Anti-pvrig antibodies and methods of use
IL257636A (en)	2018-04-30	Anti-tigit antibodies and methods of use
IL255278A0 (en)	2017-12-31	Anti-ox40 antibodies and methods of using them
ZA201606630B (en)	2020-12-23	Anti-ox40 antibodies and methods of use
SG10201912085WA (en)	2020-02-27	Anti-cd33 antibodies and methods of use thereof
IL244762A0 (en)	2016-07-31	Effective non-blocking resistors are based on vl variable domains and vhh based products
IL249540A0 (en)	2017-02-28	Methods of treating ttp with immunoglobulin single variable domains and uses thereof
IL272949A (en)	2020-04-30	Improved treatment of atopic dermatitis using tardifitant
IL265568A (en)	2019-05-30	Methods for treating TIM-3 elevation
HK1236434A1 (en)	2018-03-29	Methods of treating ttp with immunoglobulin single variable domains and uses thereof